NASDAQ
MACK

Merrimack Pharmaceuticals Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Merrimack Pharmaceuticals Inc Stock Price

Vitals

Today's Low:
$12.26
Today's High:
$12.42
Open Price:
$12.265
52W Low:
$3
52W High:
$13.66
Prev. Close:
$12.26
Volume:
22836

Company Statistics

Market Cap.:
$175.58 million
Book Value:
1.329
Revenue TTM:
$0
Operating Margin TTM:
0%
Gross Profit TTM:
$-9100000
Profit Margin:
0%
Return on Assets TTM:
-8.45%
Return on Equity TTM:
-9.78%

Company Profile

Merrimack Pharmaceuticals Inc had its IPO on 2012-03-29 under the ticker symbol MACK.

The company operates in the Healthcare sector and Biotechnology industry. Merrimack Pharmaceuticals Inc has a staff strength of 0 employees.

Stock update

Shares of Merrimack Pharmaceuticals Inc opened at $12.27 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $12.26 - $12.42, and closed at $12.36.

This is a +0.82% increase from the previous day's closing price.

A total volume of 22,836 shares were traded at the close of the day’s session.

In the last one week, shares of Merrimack Pharmaceuticals Inc have increased by +0.98%.

Merrimack Pharmaceuticals Inc's Key Ratios

Merrimack Pharmaceuticals Inc has a market cap of $175.58 million, indicating a price to book ratio of 11.9369 and a price to sales ratio of 0.

In the last 12-months Merrimack Pharmaceuticals Inc’s revenue was $0 with a gross profit of $-9100000 and an EBITDA of $-2784000. The EBITDA ratio measures Merrimack Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Merrimack Pharmaceuticals Inc’s operating margin was 0% while its return on assets stood at -8.45% with a return of equity of -9.78%.

In Q2, Merrimack Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Merrimack Pharmaceuticals Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG
0.07

Its diluted EPS in the last 12-months stands at $-0.11 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0.07. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Merrimack Pharmaceuticals Inc’s profitability.

Merrimack Pharmaceuticals Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -70.7575. Its price to sales ratio in the trailing 12-months stood at 0.

Merrimack Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 57.71% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$19.45 million
Total Liabilities
$411000.00
Operating Cash Flow
$-8811000.00
Capital Expenditure
$0
Dividend Payout Ratio
0%

Merrimack Pharmaceuticals Inc ended 2024 with $19.45 million in total assets and $0 in total liabilities. Its intangible assets were valued at $19.45 million while shareholder equity stood at $19.04 million.

Merrimack Pharmaceuticals Inc ended 2024 with $0 in deferred long-term liabilities, $411000.00 in other current liabilities, 1343000.00 in common stock, $-548298000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $10.13 million and cash and short-term investments were $18.97 million. The company’s total short-term debt was $0 while long-term debt stood at $0.

Merrimack Pharmaceuticals Inc’s total current assets stands at $19.44 million while long-term investments were $0 and short-term investments were $8.84 million. Its net receivables were $0 compared to accounts payable of $80000.00 and inventory worth $0.

In 2024, Merrimack Pharmaceuticals Inc's operating cash flow was $-8811000.00 while its capital expenditure stood at $0.

Comparatively, Merrimack Pharmaceuticals Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$12.36
52-Week High
$13.66
52-Week Low
$3
Analyst Target Price
$4

Merrimack Pharmaceuticals Inc stock is currently trading at $12.36 per share. It touched a 52-week high of $13.66 and a 52-week low of $13.66. Analysts tracking the stock have a 12-month average target price of $4.

Its 50-day moving average was $12.05 and 200-day moving average was $12.01 The short ratio stood at 13.48 indicating a short percent outstanding of 0%.

Around 120.8% of the company’s stock are held by insiders while 5289.8% are held by institutions.

Frequently Asked Questions About Merrimack Pharmaceuticals Inc

The stock symbol (also called stock or share ticker) of Merrimack Pharmaceuticals Inc is MACK

The IPO of Merrimack Pharmaceuticals Inc took place on 2012-03-29

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$60.24
-0.57
-0.94%
$17.41
0.29
+1.69%
$109.02
0.42
+0.39%
$0.6
0.02
+2.92%
$133.2
0.45
+0.34%
$1281.7
0.75
+0.06%
$12.36
0.11
+0.9%
$3.35
0.08
+2.45%
Valhi Inc (VHI)
$13.42
0.72
+5.67%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

Address

One Broadway, Cambridge, MA, United States, 02142